BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 16681716)

  • 1. Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures.
    Tentes AA; Mirelis CG; Markakidis SK; Bekiaridou KA; Bougioukas IG; Xanthoulis AI; Tsalkidou EG; Zafiropoulos GH; Nikas IH
    Int J Gynecol Cancer; 2006; 16(2):490-5. PubMed ID: 16681716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
    Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
    Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
    Zhao D; Wu LY; Wang XB; Li XG
    Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer?
    Ayhan A; Taskiran C; Yigit-Celik N; Bozdag G; Gultekin M; Usubutun A; Guler N; Yuce K
    Int J Gynecol Cancer; 2006; 16(2):484-9. PubMed ID: 16681715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative morbidity and mortality in octogenarians with ovarian cancer.
    Walters CL; Schneider KE; Whitworth JM; Fauci JM; Smith HJ; Barnes MN; Straughn JM
    Int J Gynecol Cancer; 2013 Jul; 23(6):1006-9. PubMed ID: 23714708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
    Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
    Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.
    Saha A; Varughese M; Gallagher CJ; Orphanos G; Wilson P; Oram D; Jeyarajah A; Reynolds K; Shepherd J; McCormack M; Olaitan A; McDonald N; Mould T; McNeish I; Ledermann JA
    Int J Gynecol Cancer; 2012 May; 22(4):566-72. PubMed ID: 22426404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?
    Rocconi RP; Sullivan P; Long B; Blaize M; Brown J; Arbuckle J; Bevis K; Estes JM; Reed E; Finan MA
    Int J Gynecol Cancer; 2012 Jun; 22(5):786-91. PubMed ID: 22552832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer.
    Fotopoulou C; Richter R; Braicu IE; Schmidt SC; Neuhaus P; Lichtenegger W; Sehouli J
    Ann Surg Oncol; 2011 Jan; 18(1):49-57. PubMed ID: 20697821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between retroperitoneal lymphadenectomy and survival in advanced ovarian cancer patients.
    Fang C; Zhang Y; Zhao L; Chen X; Xia L; Zhang P
    BMC Cancer; 2020 Jul; 20(1):654. PubMed ID: 32660444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.
    Van de Putte G; Oben J; Prenen L; Schobbens JC; Vlasselaer J; Van Holsbeke C; Debrock G; Van Eycken P; de Jonge E
    Int J Gynecol Cancer; 2015 Jul; 25(6):993-9. PubMed ID: 25914962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
    Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
    Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
    Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematogenous Splenic Metastases as an Independent Negative Prognosis Factor at the Moment of Primary Cytoreduction in Advanced Stage Epithelial Ovarian Cancer--A Single Center Experience.
    Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
    Anticancer Res; 2015 Oct; 35(10):5649-54. PubMed ID: 26408738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
    Ren Y; Shi T; Jiang R; Yin S; Wang P; Zang R
    Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit.
    Bacalbasa N; Dima S; Brasoveanu V; David L; Balescu I; Purnichescu-Purtan R; Popescu I
    World J Surg Oncol; 2015 Aug; 13():235. PubMed ID: 26243426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer.
    Kommoss S; Rochon J; Harter P; Heitz F; Grabowski JP; Ewald-Riegler N; Haberstroh M; Neunhoeffer T; Barinoff J; Gomez R; Traut A; du Bois A
    Ann Surg Oncol; 2010 Jan; 17(1):279-86. PubMed ID: 19898901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.